

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Calcium gluconate hydrate

April 21, 2026

Therapeutic category

Calcium compounds and preparations

Non-proprietary name

Calcium gluconate hydrate

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.
 This English version is intended to be a reference material to provide convenience for users.
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current		Revision	
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) <u>Patients receiving cardiac glycosides</u>		2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) (Deleted)	
10. INTERACTIONS <u>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</u>		10. INTERACTIONS (Deleted)	
<u>Drugs</u>	<u>Signs, symptoms, and treatment</u>	<u>Mechanism/risk factors</u>	
<u>Cardiac glycosides</u> <u>Metildigoxin</u> <u>Digoxin, etc.</u>	<u>The effects of cardiac glycosides may be enhanced to induce toxic symptoms such as bradycardia, ventricular extrasystoles, and atrioventricular block.</u>	<u>Calcium enhances the cardiac contractility-enhancing effects of cardiac glycosides.</u>	
10.2 Precautions for Co-administration (This drug should be administered with caution when co-administered with the following.) (N/A)		10.2 Precautions for Co-administration (This drug should be administered with caution when co-administered with the following.)	
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	
<u>Cardiac glycosides</u>	<u>The effects of cardiac</u>	<u>Calcium</u>	

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.
 This English version is intended to be a reference material to provide convenience for users.
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

	<u>Metildigoxin</u> <u>Digoxin</u> <u>Deslanoside</u>	<u>glycosides may be</u> <u>enhanced to induce toxic</u> <u>symptoms such as</u> <u>bradycardia, ventricular</u> <u>extrasystoles,</u> <u>atrioventricular block, and</u> <u>ventricular tachycardia. Co-</u> <u>administration with these</u> <u>drugs should be avoided</u> <u>unless it is considered</u> <u>therapeutically essential. If</u> <u>co-administration is</u> <u>inevitable, monitoring using</u> <u>an electrocardiogram, etc.</u> <u>should be performed to deal</u> <u>with the occurrence of</u> <u>arrhythmia. In addition,</u> <u>usage in such a way as to</u> <u>rapidly increase calcium</u> <u>concentration should be</u> <u>avoided.</u>	<u>enhances the</u> <u>cardiac</u> <u>contractility-</u> <u>enhancing effects</u> <u>of cardiac</u> <u>glycosides.</u>
--	---	--	---

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.